PHOENIX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology leader in regenerative medicine, is pleased to announce the successful completion of an independent interim safety review by the Data Safety Monitoring Board (DSMB) for its ADAPT clinical trial. The trial evaluated CELZ-201, a novel therapeutic perinatal tissue derived cell product, designed to treat chronic lower back pain associated with degenerative disc disease. The DSMB reviewed safety data from the first five dosed patients concluding that the trial may proceed as planned, underscoring the safety profile of CELZ-201 and supporting the advancement of this innovative th

PHOENIX, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, announced today that it has entered into definitive securities purchase agreements with certain institutional investors for the purchase and sale of 418,552 shares of the Company's common stock at an offering price of $4.42 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue warrants to purchase up to 8

PHOENIX, July 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has initiated its planned program to diagnose and treat patients exposed to biological and chemical weapons by combining Artificial Intelligence (AI) with the Company's proprietary human induced pluripotent stem cells ("iPSC"). This iPSC clinical line is part of the Company's iPSCelz® program. "The program is designed to utilize the predictive capa

PHOENIX, July 10, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update highlighting recent developments of note. "As we enter the second half of 2024, it is an opportune time to reflect on our recent achievements," said Timothy Warbington, Chief Executive Officer. "Many of our successes thus far in 2024 were the result of investments we have made in prior years combined with our steadfast adherence to operating a lean corporate structure, and engagin

PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has successfully generated human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin. The iPSC clinical line that generated these insulin producing Islet Cells is part of the Company's iPSCelz® program, which is validated by Greenstone Biosciences Inc. ("Greenstone"). The iPSC clinical line, which is currently utilized in a number of our FDA cleared

Creative Medical Technology Holdings, Inc., ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024. "In the past year our achievements have been some of the most consequential in the history of Creative Medical Technology," said Timothy Warbington, the Company's Chief Executive Officer. "Recent FDA approvals of our novel and potentially life altering regenerative medicine therapies validate the investments we have made into advancing their development, wh

Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals. This groundbreaking therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in medical history. This personalized medicine approach, focusing on a single high-risk patient, demonstrates the company's dedication to innovative, tailored healthcare solutions. Tim Warbington, CEO of Creative Medic

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CELZ-101, ImmCelzTM. This cutting-edge therapy is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation, a significant advancement for individuals dealing with brittle Type 1 diabetes, a condition characterized by extreme fluctuations in blood glucose levels. CELZ-101, also known as Supercharged Treg Bio

PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine® treatment known as AlloStem™. This study aims to determine the safety, efficacy and tolerability of CELZ-201-DDT, a proprietary, ready-to-use cell line developed by the company. The trial will focus on individuals with chronic lower back pain, providing them with an AlloStem™ injection surrounding the affected disc(s) using an ultrasound-guided, non-surgical procedure that is radiation-free. This delivery method aims to repair and remodel the surrounding ti

Continuing to Advance Regenerative Therapies for Diabetes and Chronic Lower Back Pain Strong Financial Position with No Long-Term Debt  PHOENIX, Nov. 15, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided an update on recent business activities in connection with the filing of its Form 10-Q with the Securities and Exchange Commission.   "We continue to make p